Background: The Staphylococcus aureus intracellular reservoir is associated with bone and joint infection (BJI) chronicity. As daptomycin is increasingly prescribed in BJI, strategies for improving its reduced intracellular activity should be promoted.
Introduction
Daptomycin is increasingly used for the treatment of staphylococcal bone and joint infection (BJI), 1 because of its acceptable bone diffusion, 2 and its activity against bacteria embedded in biofilms, 3 thereby targeting an important pathophysiological pathway implicated in chronic and/or orthopaedic-device-associated BJI. 4 In this setting, Staphylococcus aureus persistence within bone cells has been pointed out as another major mechanism associated with BJI chronicity and relapse. [5] [6] [7] Although not currently taken into consideration in the establishment of antimicrobial therapy guidelines for S. aureus BJI, the ability of an antimicrobial to target intracellular S. aureus represents a pivotal therapeutic feature in chronic infections. In a previous study evaluating the intraosteoblastic activity of the main antistaphylococcal drugs, 8 daptomycin revealed a weak intracellular activity. Consequently, strategies aiming to improve daptomycin activity against the intracellular reservoir of S. aureus should be promoted.
Several in vitro, in vivo and clinical studies have shown a potential synergy of daptomycin with various companion drugs, In this context, the efficacy of daptomycin, oxacillin and ceftaroline alone or in combination against intracellular MSSA and MRSA was assessed in an ex vivo model of human osteoblastic cell infection.
Materials and methods

Bacterial strains
All experiments were performed using the MRSA strain LUG359 (COL strain) 11 and its MSSA isogenic counterpart obtained by inactivation of the mecA gene by allelic replacement. Briefly, the deletion/replacement mecA::kana mutant of S. aureus LUG359 (COL strain) was obtained by using pMAD, a thermo-sensitive plasmid that contains a constitutively expressed b-galactosidase gene, thus allowing positive selection of double crossing over by following the b-galactosidase activity on X-gal agar plates.
12
MG63 osteoblastic cell culture and infection
The activity of daptomycin and b-lactams was evaluated in a lysostaphinprotection assay, as previously described. 8 Briefly, MG63 osteoblastic cells (CRL-1427; LGC standard, USA) were seeded at 40000 cells per well into 48-well tissue culture plates and cultured for 24 h until 70%-80% confluence. These cultured osteoblasts were then infected with bacterial suspensions standardized in brain heart infusion broth at an moi of 100 using a previously established clone-specific regression formula correlating the bacterial concentration with the OD at 600 nm (data not shown). After 2 h of co-culture, cell cultures were washed and incubated for 1 h with growth medium supplemented with 10 lg/mL lysostaphin (Sigma-Aldrich, SaintQuentin Fallavier, France) to kill the remaining extracellular staphylococcal cells. All supernatants were plated on Columbia agar supplemented with 5% sheep blood (COS; bioMérieux, Marcy-l'Étoile, France) and were confirmed sterile in culture.
Antimicrobial intracellular activity
The infected cells were then incubated for 24 h with growth medium containing the tested antimicrobials alone or in combination at the intraosseous concentrations reached in humans when using standard therapeutic dosages (Table 1) . 2, 13 Lysostaphin at 10 lg/mL was also added to the growth medium to specifically kill the bacteria released upon host cell lysis, thus preventing these bacteria from re-infecting new host cells.
After 24 h, the osteoblasts were washed twice and subsequently lysed by a 10 min incubation with sterile water. Dilutions of sonicated cell lysates were spiral-plated in duplicate on COS using an easySpiral V R automated plater (Interscience, Saint-Nom-la-Bretèche, France). After overnight incubation at 37 C, the colonies were enumerated using a Scan V R 1200 automated plate reader (Interscience). In parallel, the number of remaining viable cells was evaluated by MTT tetrazolium reduction assay.
In vitro determination of MICs and synergies
Effects of daptomycin/oxacillin or daptomycin/ceftaroline combinations on the tested strains were assessed using the chequerboard method as previously described, 14 using Mueller-Hinton broth (MHB) complemented with Ca 2! (50 mg/L) and Mg 2! (12.5 mg/L), and adjusted to pH 7 or at pH 5 (by adding hydrochloric acid to mimic the intralysosomal compartment, which represents the main intracellular reservoir of S. aureus). Daptomycin was serially 2-fold diluted along the ordinate ranging from 4 to 0.062 mg/L. The b-lactam antibiotic was diluted along the abscissa. Ceftaroline concentration ranged from 4 to 0.0039 mg/L, while oxacillin concentration ranged from 32 to 0.031 mg/L, except for MRSA testing at pH 7, for which oxacillin concentration ranged from 256 to 0.25 mg/L. The broth microdilution plates were inoculated with 50 lL of standardized (turbidity equivalent to that of a 0.5 McFarland standard) and diluted (1/100) bacterial suspensions and incubated for 24 h at 37 C before reading for visual turbidity using a magnifying mirror reader. The MICs of drugs A and B singly (MIC A and MIC B ) and in combination (MIC AB and MIC BA ) were determined using the first nonturbid well in each row and column. The fractional inhibitory concentration index (FICI) was calculated for each combination by using the following formula: FICI " (MIC AB /MIC A ) ! (MIC BA /MIC B ). The FICIs were interpreted as follows: 0.5, synergy; .0.5 to 1, additivity; .1 to 4, indifference; and .4, antagonism.
Statistical analysis
Each antimicrobial or combination was evaluated in triplicate during three independent experiments. Results were expressed as the number of intracellular cfu/100000 viable cells at 24 h and normalized to untreated cells, and presented as the mean of the nine measure points available for each condition and its 95% CI. Conditions were compared using the MannWhitney U-test. All analyses were performed using GraphPad-Prism v5.03 (GraphPad Software, San Diego, CA, USA).
Results
Intraosteoblastic activity of antimicrobials alone and in combination against MSSA (Figure 1a ) and MRSA (Figure 1b) In comparison with untreated cells, daptomycin failed to reduce the intracellular MSSA inoculum [!5.7% (95% CI #12.1%, !23.6%)] but was significantly active against intraosteoblastic MRSA [#27.6% (95% CI #37.0%, #18.2%); P , 10
#3
]. A significant reduction in the intracellular inoculum was observed in oxacillintreated cells, estimated at #23.9% (95% CI #40.3%, #7.5%) for Dupieux et al.
MSSA and #43.2% (95% CI #52.9%, #33.5%) for MRSA (P " 0.019 and P , 10
#4
, respectively), surprisingly. Finally, the observed reduction in intracellular inoculum with ceftaroline was estimated at #33.1% (95% CI #40.3%, #25.9%; P , 10 #4 ) and #28.9% (95% CI #44.2%, #13.6%; P , 10
#2
) for MSSA and MRSA, respectively. The activity of the combination of daptomycin and oxacillin against intracellular MSSA [#44.4% (95% CI #51.8%, #37.0%)] and MRSA [#57.2% (95% CI #65.7%, #48.7%)] was significantly higher than daptomycin (P , 10
#3
) and oxacillin (P , 0.05) alone. Conversely, no statistical difference was observed between the activities of the daptomycin/ceftaroline combination compared with ceftaroline.
In vitro susceptibility studies and impact of pH
In vitro MICs of the three tested molecules for both MSSA and MRSA strains are presented in Table 1 . Decreasing the pH from 7 to 5 resulted in a significant decrease in b-lactam MICs: oxacillin MIC dropped from .256 to 0.023 mg/L for MRSA and from 0.25 to 0.016 mg/L for MSSA. Similarly, ceftaroline MICs were reduced by 20-and 30-fold for MSSA and MRSA, respectively. Conversely, a 12-fold increase in daptomycin MIC for MSSA was observed at pH 5, resulting in an MIC of 0.75 mg/L, remaining below the EUCAST susceptibility breakpoint of 1 mg/L. MRSA susceptibility to daptomycin was not impacted by pH conditions. Using the chequerboard method, an additive effect was observed with the daptomycin/oxacillin combination against MRSA at pH 5, but not at pH 7. Daptomycin and ceftaroline were additive against MSSA at pH 7 only. The other associations were indifferent whatever the pH.
Discussion
To our knowledge, the present study is the first evaluation of daptomycin/b-lactam combination therapy against intraosteoblastic S. aureus, and expands the previous results obtained in our in vitro osteoblastic cell line infection model regarding the individual intracellular activity of antistaphylococcal drugs at intraosseous concentrations when used in standard therapeutic regimens. 8 This last point is of great importance, as conventional studies using plasmatic or gradually increasing concentrations have difficulty finding resonance in the clinical setting as not reflecting human therapeutic tissue concentrations. Despite evaluating a single MRSA strain and its MSSA isogenic counterpart, these results provide interesting insights into intraosteoblastic S. aureus eradication, with the aim of enhancing the weak intracellular activity of daptomycin.
Considering the intraosteoblastic activity of the antimicrobials alone, our findings confirmed several pivotal points relating to targeting the intracellular S. aureus reservoir. First, daptomycin has a weak intraosteoblastic activity, as also shown within human monocyte-derived macrophages. 15 This decreased efficacy does not seem to be related to the acid pH conditions encountered within the lysosomal compartment, as daptomycin MICs were not influenced by pH in vitro. Conversely, oxacillin remains active intracellularly, even against MRSA. The restoration of activity of b-lactams against MRSA is supposed to partly rely on a pH-induced Intraosteoblastic daptomycin/b-lactam synergy JAC conformational change of PBP2a allowing acylation by the b-lactams. 16 Similarly, Baudoux et al. 17 showed that lowering the pH from 7.4 to 5.4 linearly increased the activity of oxacillin, with a 10-fold decrease in MIC for an MSSA isolate. Regarding MRSA, the impact of pH on MICs of penicillins and penems seems higher than that on cephalosporin MICs. 18 Our results suggest that ceftaroline is an exception within cephalosporins, with a significant decrease in MICs for both MSSA and MRSA at low pH.
Regarding daptomycin-based combination therapies, b-lactams are considered to be preferred candidates, as a synergy against numerous MRSA isolates has been reported in vitro and in experimental models of endocarditis or foreign body infection. 10 Data regarding MSSA are more limited, but a recent study suggested that daptomycin/cloxacillin may be as efficient as cloxacillin/rifampicin in a tissue-cage MSSA infection model. 19 Recent in vitro studies have shown similar results concerning the combination of daptomycin with new anti-MRSA cephalosporins. 20 Our results confirmed the benefit of the daptomycin/oxacillin combination when considering intracellular S. aureus eradication, even though no additional or synergic effects were highlighted in vitro against the tested strains at pH 7. The significant improvement of oxacillin activity at acidic pH allows the improvement of the intracellular activity of daptomycin thanks to a pH-dependent addition effect. Conversely, the enhancement of ceftaroline activity at lower pH does not allow offsetting the weak daptomycin activity in the intracellular compartment, despite an additional effect observed at pH 7 against the tested MRSA.
In conclusion, acidic intracellular conditions may lead to a significant improvement of oxacillin activity against MSSA but also MRSA, which counterbalances the daptomycin weak intracellular activity offering an additional therapeutic effect not observed with ceftaroline. The ability of the daptomycin/oxacillin combination to target the intracellular reservoir argues for further clinical evaluation in S. aureus BJI.
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